Oncologic Applications of Positron Emission Tomography (PET) Scanning
FDG-PET or FDG-PET/CT may be considered medically necessary for listed cancers when specific criteria are met, such as staging or restaging of muscle-invasive bladder cancer, Ewing sarcoma and osteosarcoma, brain cancer, lymphoma, and multiple myeloma. PET for surveillance, meaning scans performed more than 6 months after completion of cancer therapy (12 months for lymphoma) in individuals without objective signs or symptoms of recurrence, is considered investigational, and fluoroestradiol F18 PET in individuals with breast cancer is considered investigational. The medically necessary situations assume that the PET results will influence treatment decisions, and if the results will not influence treatment decisions, those situations are considered not medically necessary.